SonoThera is developing an ultrasound-mediated nonviral gene therapy platform that utilizes microbubbles for targeted delivery of genetic medicines to various human organs. This technology addresses the challenges of safety, efficacy, and biodistribution in gene therapy, enabling the delivery of large nucleic acid payloads without invasive procedures.
Funding
$60.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current gene therapy approaches face challenges related to safety, efficacy, biodistribution, and manufacturing costs, limiting their broad application. Invasive procedures are often required for delivery, and controlling the distribution of genetic medicines to specific organs remains a significant hurdle.
Solution
SonoThera is developing a non-viral gene therapy platform that uses ultrasound and microbubbles to enable targeted delivery of genetic medicines. This approach allows for non-invasive delivery to a wide range of human organs, overcoming limitations associated with traditional viral vectors. The platform is designed to deliver diverse nucleic acid payloads of significant size, enhancing its versatility across various therapeutic applications. By using ultrasound microbubbles and hardware with established safety profiles, SonoThera aims to improve the safety, efficacy, and biodistribution of gene therapies while reducing manufacturing costs.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and clinical partners focused on developing gene therapies for a wide range of diseases.
Features
- Ultrasound-mediated delivery for non-invasive and targeted gene therapy.
- Microbubble technology to enhance the delivery of genetic medicines to specific organs.
- Capability to deliver a diversity of large nucleic acid payloads.
- Platform designed to overcome key barriers in gene therapy, including safety and biodistribution.
- Potential for reduced manufacturing costs compared to viral-based gene therapies.
- Sonoporation technology with preclinical and clinical validation.